よむ、つかう、まなぶ。
09参考資料１－３ ９価ヒトパピローマウイルス（ HPV ）ワクチン ファクトシート (45 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000192554_00024.html |
| 出典情報 | 厚生科学審議会予防接種・ワクチン分科会 予防接種基本方針部会（第49回 10／4）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
1840
intraepithelial neoplasia in Japan: A nationwide case-control study. Cancer Sci. doi:
1876
papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and
1841
10.1111/cas.14682. Online ahead of print.
1877
poliomyelitis vaccines to healthy adolescents 11-15 years of age. Pediatr Infect Dis J 34(6):
1842
106.
1878
627-634.
1843
Combined Analysis of 7 Phase III Clinical Trials. Pediatrics 138(2)
1879
116.
1844
https://pediatrics.aappublications.org/content/pediatrics/138/132/e20154387.full.pdf
1880
Vaccine. Pediatrics 144(6)
Moreira, E. D., Jr., et al. (2016). Safety Profile of the 9-Valent HPV Vaccine: A
Shimabukuro, T. T., et al. (2019). Safety of the 9-Valent Human Papillomavirus
1845
107. Ruiz-Sternberg, A. M., et al. (2018). Efficacy, immunogenicity, and safety of a 9-valent
1881
https://pediatrics.aappublications.org/content/pediatrics/144/146/e20191791.full.pdf
1846
human papillomavirus vaccine in Latin American girls, boys, and young women.
1882
117. Donahue, J. G., et al. (2019). Near Real-Time Surveillance to Assess the Safety of the
1847
Papillomavirus Res 5: 63-74.
1883
9-Valent Human Papillomavirus Vaccine. Pediatrics 144(6)
1848
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887018/pdf/main.pdf
1884
https://pediatrics.aappublications.org/content/pediatrics/144/146/e20191808.full.pdf
1849
108. Joura, E. A., et al. (2015). A 9-valent HPV vaccine against infection and intraepithelial
1885
118. Costa, A. P. F., et al. (2017). Safety of Human Papillomavirus 9-Valent Vaccine: A
1850
neoplasia in women. N Engl J Med 372(8): 711-723.
1886
Meta-Analysis of Randomized Trials. J Immunol Res 2020.
1851
https://pubmed.ncbi.nlm.nih.gov/25693011/
1887
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546048/pdf/JIR5542017-3736201.pdf
1852
109. Van Damme, P., et al. (2015). Immunogenicity and Safety of a 9-Valent HPV Vaccine.
1888
119.
1853
Pediatrics 136(1): e28-39.
1889
Cochrane review of randomized trials. Expert Rev Vaccines 17(12): 1085-1091.
1854
https://pediatrics.aappublications.org/content/pediatrics/136/131/e128.full.pdf
1890
https://www.tandfonline.com/doi/pdf/10.1080/14760584.2018.1548282?needAccess=true
1855
110. Castellsague, X., et al. (2015). Immunogenicity and safety of the 9-valent HPV vaccine
1891
120. Genovese, C., et al. (2018). HPV vaccine and autoimmune diseases: systematic review
1856
in men. Vaccine 33(48): 6892-6901.
1892
and meta-analysis of the literature. J Prev Med Hyg 59(3): E194-e199.
1857
https://www.sciencedirect.com/science/article/pii/S0264410X15009032
1893
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196376/pdf/jpmh-6192018-6196303-
1858
111.
1894
e6196194.pdf
1859
Vaccine With Meningococcal and Tdap Vaccines. Pediatrics 136(3): e563-572.
1895
121. 祖⽗江友孝. ⻘少年における「疼痛⼜は運動障害を中⼼とする多様な症状」の受療
1860
https://scholarworks.iupui.edu/bitstream/handle/1805/9429/Schilling_2015_coadministrat
1896
状 況 に 関 す る 全 国 疫 学 調 査 ． https://www.mhlw.go.jp/file/05-Shingikai-10601000-
1861
ion.pdf
1897
Daijinkanboukouseikagakuka-Kouseikagakuka/0000161352.pdf
1862
112. Garland, S. M., et al. (2015). Safety and immunogenicity of a 9-valent HPV vaccine in
1898
122. Suzuki, S. and A. Hosono (2018). No association between HPV vaccine and reported
1863
females 12-26 years of age who previously received the quadrivalent HPV vaccine. Vaccine
1899
post-vaccination symptoms in Japanese young women: Results of the Nagoya study.
1864
33(48): 6855-6864.
1900
Papillomavirus Res 5: 96-103.
1865
https://www.sciencedirect.com/science/article/pii/S0264410X1501187
1901
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887012/pdf/main.pdf
1866
113.
Moreira, E. D., et al. (2018). Safety profile of the 9-valent human papillomavirus
1902
123. 平井 利明，⿊岩 義之．(2019).【呼吸の謎 2019】複数回の呼吸停⽌後に⼈⼯呼吸器
1867
vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years
1903
管理を要したヒトパピローマウイルスワクチン関連神経免疫異常症候群の 1 例．脳神経内
1868
of age. Hum Vaccin Immunother 14(2): 396-403.
1904
科 2019；91：619-629. http://search.jamas.or.jp/link/ui/2020084047
124. Hikiami, R., et al. (2018). Amyotrophic Lateral Sclerosis after Receiving the Human
Schilling, A., et al. (2015). Coadministration of a 9-Valent Human Papillomavirus
Arbyn, M. and L. Xu (2018). Efficacy and safety of prophylactic HPV vaccines. A
1869
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806635/pdf/khvi-5806614-5806602-
1905
1870
1403700.pdf
1906
Papilloma Virus Vaccine: A Case Report of a 15-year-old Girl. Intern Med 57(13): 1917-1919.
1871
114.
Van Damme, P., et al. (2016). A phase III clinical study to compare the
1907
125. Choi, J. Y., et al. (2017). Case of lupus erythematosus panniculitis triggered by human
1872
immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine
1908
papillomavirus quadrivalent vaccine injection. J Dermatol 44(12): 1420-1421.
1873
34(35): 4205-4212.
1909
https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.13735
1874
https://www.sciencedirect.com/science/article/pii/S0264410X16304807
1910
126. ⾼嶋 博，荒⽥ 仁.(2018).ヒトパピローマウイルスワクチン由来の新規視床下部症候
1875
115. Kosalaraksa, P., et al. (2015). An open-label, randomized study of a 9-valent human
1911
群に関する基礎的、臨床的洞察
89
ヒトパピローマウイルスワクチン接種後の神経障害．⾃律
90
intraepithelial neoplasia in Japan: A nationwide case-control study. Cancer Sci. doi:
1876
papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and
1841
10.1111/cas.14682. Online ahead of print.
1877
poliomyelitis vaccines to healthy adolescents 11-15 years of age. Pediatr Infect Dis J 34(6):
1842
106.
1878
627-634.
1843
Combined Analysis of 7 Phase III Clinical Trials. Pediatrics 138(2)
1879
116.
1844
https://pediatrics.aappublications.org/content/pediatrics/138/132/e20154387.full.pdf
1880
Vaccine. Pediatrics 144(6)
Moreira, E. D., Jr., et al. (2016). Safety Profile of the 9-Valent HPV Vaccine: A
Shimabukuro, T. T., et al. (2019). Safety of the 9-Valent Human Papillomavirus
1845
107. Ruiz-Sternberg, A. M., et al. (2018). Efficacy, immunogenicity, and safety of a 9-valent
1881
https://pediatrics.aappublications.org/content/pediatrics/144/146/e20191791.full.pdf
1846
human papillomavirus vaccine in Latin American girls, boys, and young women.
1882
117. Donahue, J. G., et al. (2019). Near Real-Time Surveillance to Assess the Safety of the
1847
Papillomavirus Res 5: 63-74.
1883
9-Valent Human Papillomavirus Vaccine. Pediatrics 144(6)
1848
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887018/pdf/main.pdf
1884
https://pediatrics.aappublications.org/content/pediatrics/144/146/e20191808.full.pdf
1849
108. Joura, E. A., et al. (2015). A 9-valent HPV vaccine against infection and intraepithelial
1885
118. Costa, A. P. F., et al. (2017). Safety of Human Papillomavirus 9-Valent Vaccine: A
1850
neoplasia in women. N Engl J Med 372(8): 711-723.
1886
Meta-Analysis of Randomized Trials. J Immunol Res 2020.
1851
https://pubmed.ncbi.nlm.nih.gov/25693011/
1887
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546048/pdf/JIR5542017-3736201.pdf
1852
109. Van Damme, P., et al. (2015). Immunogenicity and Safety of a 9-Valent HPV Vaccine.
1888
119.
1853
Pediatrics 136(1): e28-39.
1889
Cochrane review of randomized trials. Expert Rev Vaccines 17(12): 1085-1091.
1854
https://pediatrics.aappublications.org/content/pediatrics/136/131/e128.full.pdf
1890
https://www.tandfonline.com/doi/pdf/10.1080/14760584.2018.1548282?needAccess=true
1855
110. Castellsague, X., et al. (2015). Immunogenicity and safety of the 9-valent HPV vaccine
1891
120. Genovese, C., et al. (2018). HPV vaccine and autoimmune diseases: systematic review
1856
in men. Vaccine 33(48): 6892-6901.
1892
and meta-analysis of the literature. J Prev Med Hyg 59(3): E194-e199.
1857
https://www.sciencedirect.com/science/article/pii/S0264410X15009032
1893
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196376/pdf/jpmh-6192018-6196303-
1858
111.
1894
e6196194.pdf
1859
Vaccine With Meningococcal and Tdap Vaccines. Pediatrics 136(3): e563-572.
1895
121. 祖⽗江友孝. ⻘少年における「疼痛⼜は運動障害を中⼼とする多様な症状」の受療
1860
https://scholarworks.iupui.edu/bitstream/handle/1805/9429/Schilling_2015_coadministrat
1896
状 況 に 関 す る 全 国 疫 学 調 査 ． https://www.mhlw.go.jp/file/05-Shingikai-10601000-
1861
ion.pdf
1897
Daijinkanboukouseikagakuka-Kouseikagakuka/0000161352.pdf
1862
112. Garland, S. M., et al. (2015). Safety and immunogenicity of a 9-valent HPV vaccine in
1898
122. Suzuki, S. and A. Hosono (2018). No association between HPV vaccine and reported
1863
females 12-26 years of age who previously received the quadrivalent HPV vaccine. Vaccine
1899
post-vaccination symptoms in Japanese young women: Results of the Nagoya study.
1864
33(48): 6855-6864.
1900
Papillomavirus Res 5: 96-103.
1865
https://www.sciencedirect.com/science/article/pii/S0264410X1501187
1901
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887012/pdf/main.pdf
1866
113.
Moreira, E. D., et al. (2018). Safety profile of the 9-valent human papillomavirus
1902
123. 平井 利明，⿊岩 義之．(2019).【呼吸の謎 2019】複数回の呼吸停⽌後に⼈⼯呼吸器
1867
vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years
1903
管理を要したヒトパピローマウイルスワクチン関連神経免疫異常症候群の 1 例．脳神経内
1868
of age. Hum Vaccin Immunother 14(2): 396-403.
1904
科 2019；91：619-629. http://search.jamas.or.jp/link/ui/2020084047
124. Hikiami, R., et al. (2018). Amyotrophic Lateral Sclerosis after Receiving the Human
Schilling, A., et al. (2015). Coadministration of a 9-Valent Human Papillomavirus
Arbyn, M. and L. Xu (2018). Efficacy and safety of prophylactic HPV vaccines. A
1869
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806635/pdf/khvi-5806614-5806602-
1905
1870
1403700.pdf
1906
Papilloma Virus Vaccine: A Case Report of a 15-year-old Girl. Intern Med 57(13): 1917-1919.
1871
114.
Van Damme, P., et al. (2016). A phase III clinical study to compare the
1907
125. Choi, J. Y., et al. (2017). Case of lupus erythematosus panniculitis triggered by human
1872
immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine
1908
papillomavirus quadrivalent vaccine injection. J Dermatol 44(12): 1420-1421.
1873
34(35): 4205-4212.
1909
https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.13735
1874
https://www.sciencedirect.com/science/article/pii/S0264410X16304807
1910
126. ⾼嶋 博，荒⽥ 仁.(2018).ヒトパピローマウイルスワクチン由来の新規視床下部症候
1875
115. Kosalaraksa, P., et al. (2015). An open-label, randomized study of a 9-valent human
1911
群に関する基礎的、臨床的洞察
89
ヒトパピローマウイルスワクチン接種後の神経障害．⾃律
90